# reload+after+2024-01-23 14:46:59.680705
address1§234 Church Street
address2§Suite 1020
city§New Haven
state§CT
zip§06510
country§United States
phone§203 859 3820
website§https://www.rallybio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
fullTimeEmployees§44
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Martin W. MacKay Ph.D.', 'age': 67, 'title': 'Co-Founder & Executive Chairman', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 707066, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen  Uden M.B, M.D.', 'age': 65, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 707066, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan I. Lieber M.B.A.', 'age': 53, 'title': 'CFO & Treasurer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ami  Bavishi', 'title': 'Head of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven W. Ryder F.A.C.P, M.D.', 'age': 71, 'title': 'Chief Medical Officer', 'yearBorn': 1952, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§8
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-1.992
currency§USD
dateShortInterest§1702598400
forwardEps§-2.0
exchange§NMS
quoteType§EQUITY
shortName§Rallybio Corporation
longName§Rallybio Corporation
firstTradeDateEpochUtc§1627565400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§49dd8bea-3b9a-369d-b66d-d25eaa1b0182
gmtOffSetMilliseconds§-18000000
targetHighPrice§30.0
targetLowPrice§7.0
targetMeanPrice§16.5
targetMedianPrice§15.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§12.91
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
